EA201990643A1 - Фармацевтические соединения - Google Patents

Фармацевтические соединения

Info

Publication number
EA201990643A1
EA201990643A1 EA201990643A EA201990643A EA201990643A1 EA 201990643 A1 EA201990643 A1 EA 201990643A1 EA 201990643 A EA201990643 A EA 201990643A EA 201990643 A EA201990643 A EA 201990643A EA 201990643 A1 EA201990643 A1 EA 201990643A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compounds
compound
activity
arylimidazolylisoxazole
formula
Prior art date
Application number
EA201990643A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201990643A1 publication Critical patent/EA201990643A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Соединение, которое представляет собой арилимидазолилизоксазол формулы (I), или его фармацевтически приемлемая сольСоединение обладает активностью модулятора активности P300 и/или CBP и применяется для лечения рака, в частности рака предстательной железы.
EA201990643A 2016-10-18 2017-10-18 Фармацевтические соединения EA201990643A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1617630.7A GB201617630D0 (en) 2016-10-18 2016-10-18 Pharmaceutical compounds
PCT/GB2017/053152 WO2018073586A1 (en) 2016-10-18 2017-10-18 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
EA201990643A1 true EA201990643A1 (ru) 2019-11-29

Family

ID=57680668

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990643A EA201990643A1 (ru) 2016-10-18 2017-10-18 Фармацевтические соединения

Country Status (24)

Country Link
US (2) US10696666B2 (ru)
EP (1) EP3529248B1 (ru)
JP (1) JP7152393B2 (ru)
KR (1) KR102578786B1 (ru)
CN (1) CN110049983B (ru)
AU (1) AU2017346453B2 (ru)
BR (1) BR112019007834A2 (ru)
CA (1) CA3039641A1 (ru)
CY (1) CY1123666T1 (ru)
DK (1) DK3529248T3 (ru)
EA (1) EA201990643A1 (ru)
ES (1) ES2828504T3 (ru)
GB (1) GB201617630D0 (ru)
HR (1) HRP20201444T1 (ru)
HU (1) HUE052443T2 (ru)
IL (1) IL266017B (ru)
LT (1) LT3529248T (ru)
MX (1) MX2019004113A (ru)
PT (1) PT3529248T (ru)
RS (1) RS61007B1 (ru)
SG (1) SG11201903155XA (ru)
SI (1) SI3529248T1 (ru)
WO (1) WO2018073586A1 (ru)
ZA (1) ZA201902334B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
GB201806320D0 (en) * 2018-04-18 2018-05-30 Cellcentric Ltd Process
MX2020014303A (es) 2018-06-29 2021-03-25 Forma Therapeutics Inc Inhibición de la proteína de union a creb (cbp).
WO2020190780A1 (en) * 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
CN112574189B (zh) * 2019-09-27 2024-05-31 海创药业股份有限公司 一种ep300/cbp抑制剂
CN112574178A (zh) * 2019-09-27 2021-03-30 海创药业股份有限公司 一种氘代苯并咪唑类化合物及其作为ep300/cbp抑制剂的用途
CN112574191B (zh) * 2019-09-29 2024-01-23 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用
US20230233558A1 (en) 2020-06-25 2023-07-27 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
EP4171556A1 (en) 2020-06-25 2023-05-03 Tolremo Therapeutics AG A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
TW202227429A (zh) * 2020-11-06 2022-07-16 大陸商貝達藥業股份有限公司 Ｐ３００抑制劑、包含其的藥物組合物、其應用及製備其的方法
WO2022138944A1 (ja) * 2020-12-25 2022-06-30 国立研究開発法人国立がん研究センター Ｓｗｉ／ｓｎｆ複合体機能異常がんの合成致死性に基づく治療法
WO2022143773A1 (zh) * 2020-12-31 2022-07-07 南京明德新药研发有限公司 苯并咪唑类化合物及其应用
CN114989158A (zh) * 2021-03-02 2022-09-02 复旦大学 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用
WO2022184664A1 (en) 2021-03-02 2022-09-09 Boehringer Ingelheim International Gmbh Anticancer combination therapy
EP4257130A1 (de) * 2022-04-08 2023-10-11 Justus-Liebig-Universität Gießen Inobrodib zur behandlung von pulmonaler arterieller hypertonie

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113472A0 (en) 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
ATE253915T1 (de) * 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
AU2001296799A1 (en) 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP1490058B1 (en) 2002-02-21 2007-10-10 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2004063151A2 (en) 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
US20070129353A1 (en) * 2005-11-08 2007-06-07 Michael Kahn Alpha-helix mimetics and method relating to the treatment of cancer stem cells
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CN101616587A (zh) 2006-12-05 2009-12-30 孙仲铭 吲唑化合物
KR20100023907A (ko) 2007-06-26 2010-03-04 사노피-아벤티스 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성
US20120121540A1 (en) 2007-08-10 2012-05-17 Franz Ulrich Schmitz Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
EP2234487A4 (en) 2007-12-19 2011-09-07 Scripps Research Inst ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE
US8501957B2 (en) 2008-12-10 2013-08-06 China Medical University Benzimidazole compounds and their use as anticancer agents
US20110237633A1 (en) 2008-12-11 2011-09-29 Bijoy Panicker Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2011085039A2 (en) * 2010-01-05 2011-07-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
US8946230B2 (en) 2010-05-13 2015-02-03 Amgen Inc. Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors
EP2397471A1 (en) 2010-06-16 2011-12-21 China Medical University Benzimidazole compounds and their use
JP5850503B2 (ja) 2010-09-14 2016-02-03 北海道公立大学法人 札幌医科大学 筋ジストロフィーを処置するための組成物
CA2825028A1 (en) 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
JP2014114212A (ja) 2011-03-29 2014-06-26 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
EP2858983B1 (en) 2012-06-11 2018-04-18 UCB Biopharma SPRL Tnf-alpha modulating benzimidazoles
AU2013289938A1 (en) 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
JP2016000697A (ja) 2012-10-02 2016-01-07 大日本住友製薬株式会社 ピリミジン誘導体
JP2014073982A (ja) 2012-10-03 2014-04-24 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体からなる医薬
WO2014078479A2 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
WO2014157382A1 (ja) 2013-03-29 2014-10-02 味の素株式会社 スフィンゴシンキナーゼ阻害剤
PL231063B1 (pl) 2013-04-10 2019-01-31 Oncoarendi Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
CA2915561C (en) * 2013-06-21 2020-09-22 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
WO2015023958A1 (en) 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JP6785217B2 (ja) 2014-07-31 2020-11-18 インスティチュート パスツール コリア ２−アミノ−ベンゾイミダゾール誘導体ならびにこれらの５−リポキシゲナーゼおよび／またはプロスタグランジンｅシンターゼ阻害剤としての使用
JP6771464B2 (ja) * 2014-11-27 2020-10-21 ジェネンテック， インコーポレイテッド Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
GB201506658D0 (en) * 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
US10875833B2 (en) 2015-06-12 2020-12-29 Transitions Optical, Inc. Alignment compounds
CA2994478C (en) 2015-08-12 2023-10-03 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017059252A1 (en) 2015-10-02 2017-04-06 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
WO2017100525A1 (en) 2015-12-11 2017-06-15 The Board Of Regents Of The University Of Texas System Substituted benzimidazolium, pyrido-imidazolium, or pyrazino-imidazolium compounds as chemotherapeutics
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018097976A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins

Also Published As

Publication number Publication date
PT3529248T (pt) 2020-09-03
LT3529248T (lt) 2020-10-26
HRP20201444T1 (hr) 2020-12-11
JP2019537571A (ja) 2019-12-26
WO2018073586A1 (en) 2018-04-26
KR20190075095A (ko) 2019-06-28
SI3529248T1 (sl) 2020-11-30
IL266017A (en) 2019-06-30
SG11201903155XA (en) 2019-05-30
IL266017B (en) 2021-08-31
MX2019004113A (es) 2019-09-09
CA3039641A1 (en) 2018-04-26
BR112019007834A2 (pt) 2019-07-16
JP7152393B2 (ja) 2022-10-12
US20200407349A1 (en) 2020-12-31
EP3529248B1 (en) 2020-08-19
US10696666B2 (en) 2020-06-30
HUE052443T2 (hu) 2021-04-28
DK3529248T3 (da) 2020-09-14
US11377443B2 (en) 2022-07-05
CN110049983A (zh) 2019-07-23
CN110049983B (zh) 2022-06-14
GB201617630D0 (en) 2016-11-30
ES2828504T3 (es) 2021-05-26
AU2017346453B2 (en) 2022-02-17
EP3529248A1 (en) 2019-08-28
CY1123666T1 (el) 2022-03-24
US20190375740A1 (en) 2019-12-12
AU2017346453A1 (en) 2019-05-02
KR102578786B1 (ko) 2023-09-15
ZA201902334B (en) 2022-10-26
RS61007B1 (sr) 2020-11-30

Similar Documents

Publication Publication Date Title
EA201990643A1 (ru) Фармацевтические соединения
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EP4302835A3 (en) Methods of treating ovarian cancer
EA201790660A1 (ru) Ингибитор киназ
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201690752A1 (ru) Ингибиторы g12c kras
EA201591599A1 (ru) Ингибиторы ido
EA201591823A1 (ru) Ингибиторы ido
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
EA201690027A1 (ru) Ингибиторы ido
EA201690152A1 (ru) Ингибиторы ido
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201991884A3 (ru) Ингибиторы g12c kras
EA201591340A1 (ru) Модулятор андрогенного рецептора и его применения
EA201791094A1 (ru) Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201992137A1 (ru) ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1
EA201791736A1 (ru) Комбинированная терапия для лечения рака
PH12016502353A1 (en) Pharmaceutical composition